Format

Send to

Choose Destination
Clin Lung Cancer. 2011 May;12(3):161-5. doi: 10.1016/j.cllc.2011.03.013. Epub 2011 Apr 27.

A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.

Author information

1
Vanderbilt Ingram Cancer Center, Nashville, TN, USA.

Abstract

OBJECTIVES:

Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings.

METHODS:

Patients with previously untreated ED-SCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, life expectancy ≥ 3 months, and adequate organ function were eligible. Patients were treated with carboplatin AUC 5 intravenously over 30-60 minutes on day 1, followed by CPT-11(irinotecan) 50 mg/m(2) intravenously over 30-90 minutes on days 1 and 8 every 3 weeks for 4-6 cycles at the discretion of the treating physician.

RESULTS:

Fifty-six patients were enrolled, and 50 patients were eligible. The median age of patients was 60.1 years. The most common toxicities were neutropenia, thrombocytopenia, nausea/vomiting, and dehydration. The overall response rate was 58%. Median PFS was 5.3 months, median overall survival was 9.7 months, and 1-year overall survival was 28.7%.

CONCLUSIONS:

Carboplatin and irinotecan is a safe and reasonable combination for the treatment of patients with ED-SCLC.

PMID:
21663858
DOI:
10.1016/j.cllc.2011.03.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center